The efficacy and safety of denosumab and bisphosphonates on glucocorticoid induced osteoporosis patients:a meta-analysis
10.3760/cma.j.issn.1673-4904.2019.10.002
- VernacularTitle: 狄诺塞麦与双膦酸盐治疗糖皮质激素性骨质疏松症疗效性与安全性的Meta分析
- Author:
Jing XIE
1
;
Xiaoxu YAN
1
;
Fenglian MA
1
;
Yuanyuan LIU
1
;
Xi CHEN
1
;
Lijun CAI
2
;
Dongsheng NIU
2
;
Jinhan LYU
2
;
Donggeng GUO
1
Author Information
1. Department of Rheumatism, People′s Hospital of Ningxia Hui Autonomous Region (the First Clinical College Affiliated to Northwest Minzu University) Autonomous Region People′s Hospital Affiliated to Ningxia Medical University, Yinchuan 750001, China
2. Ningxia Bone and Joint Disease Clinical Medical Research Center, People′s Hospital of Ningxia Hui Autonomous Region (the First Clinical College Affiliated to Northwest Minzu University) Autonomous Region People′s Hospital Affiliated to Ningxia Medical University, Yinchuan 750001, China
- Publication Type:Journal Article
- Keywords:
Osteoporosis;
Meta-analysis;
Denosumab;
Bisphosphonates
- From:
Chinese Journal of Postgraduates of Medicine
2019;42(10):869-874
- CountryChina
- Language:Chinese
-
Abstract:
Objective:In order to evaluate the therapeutic effects and safety of denosumab and bisphosphonates in glucocorticoid induced osteoporosis patients.
Methods:Standard studies were obtained by searching CNKI, CBM, VIP, Wanfang, Pubmed, Embase and Cochrane databases.
Results:Three RCTs with 869 patients were included in this study. It showed that the mean changes of lumbar spine, total hip and femoral neck bone mineral density (BMD) for patients in denosumab group were increased by 2.47%, 1.43% and 1.07% respectively compared to those of bisphosphonates group.There was no statistically significant difference between patients receiving denosumab and those receiving bisphosphonate in terms of adverse events and serious adverse events.
Conclusions:Denosumab has an effective increase for lumbar spine, total hip and femoral neck bone mineral density, and the safety of both is similar.
